Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease

Abstract

Angiostatin, an endogenous angiogenesis inhibitor generated by the proteolytic cleavage of plasminogen, was recently reported to contribute to the development of Alzheimer’s disease (AD). However, whether there are pathological changes in angiostatin levels in individuals with AD dementia is unclear, and whether plasma angiostatin has a relationship with major AD pathological processes and cognitive impairment remains unknown. To examine plasma angiostatin levels in patients with AD dementia and investigate the associations of angiostatin with blood and cerebrospinal fluid (CSF) AD biomarkers, we conducted a cross-sectional study including 35 cognitively normal control (CN) subjects and 59 PiB-PET-positive AD dementia patients. We found that plasma angiostatin levels were decreased in AD dementia patients compared to CN subjects. Plasma angiostatin levels were negatively correlated with plasma Aβ42 and Aβ40 levels in AD dementia patients and positively correlated with CSF total tau (t-tau) levels and t-tau/Aβ42 in AD dementia patients with APOE-ε4. In addition, plasma angiostatin levels had the potential to distinguish AD from CN. These findings suggest a link between angiostatin and AD pathogenesis and imply that angiostatin might be a potential diagnostic biomarker for AD.

Association between plasma CTRPs with cognitive impairment and neurodegeneration of Alzheimer's disease

“…In accordance with our previous study, the plasma levels of pT217, pT181, and NfL were simultaneously measured using the commercially available single-molecule array (SIMOA) Human Neurology 3-Plex A assay kit (Quanterix, USA) on board of the automated SIMOA HD-1 analyzer (Quanterix). 24 Plasma levels of CTRP3 (SEK169Hu, Cloud-Clone Corp., Hubei, China), CTRP4 (MM-1640H1, Jiangsu Meimian Industrial Co., Ltd., Jiangsu, China), and CTRP14 (SEE867Hu, Cloud-Clone Corp.) were detected using commercially available ELISA kits according to the instructions.…”

Palladium nanoballs coupled with smartphone-thermal reader for photothermal lateral flow immunoassay of Aβ 1-40

“…Since the generation of neuritic plaques composed of amyloid-β (Aβ) peptides is a major pathological hallmark of AD, Aβ is a key predictor for the early diagnosis of AD. 4–6 Amyloid beta 1-40 (Aβ 1-40) is one of the most abundant substances in the body with the capacity to form insoluble aggregates, which is a universal biomarker used for the prediction of AD. 7–9 Recent studies have demonstrated that the overexpression of Aβ 1-40 in serum predicts AD and exhibits a strong correlation with pathological changes in the brain.…”